Cargando…

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

INTRODUCTION: Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII. AIM: In this multicentre, open‐label study (HOHOEMI), we evaluated the efficacy, safety and pharmacokinetics of emicizumab in Japanese paediatric patients aged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shima, Midori, Nogami, Keiji, Nagami, Sayaka, Yoshida, Seitaro, Yoneyama, Koichiro, Ishiguro, Akira, Suzuki, Takashi, Taki, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900083/ https://www.ncbi.nlm.nih.gov/pubmed/31515851 http://dx.doi.org/10.1111/hae.13848

Ejemplares similares

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study
por: Shima, Midori, et al.
Publicado: (2022)

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A
por: Shima, Midori, et al.
Publicado: (2020)

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial
por: Ogiwara, Kenichi, et al.
Publicado: (2022)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
por: Takeyama, Masahiro, et al.
Publicado: (2023)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2021)

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors
por: Matsushita, Tadashi, et al.
Publicado: (2022)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2017)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
por: Escobar, Miguel, et al.
Publicado: (2022)

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers
por: Kotani, Naoki, et al.
Publicado: (2018)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage
por: Yamada, Yuya, et al.
Publicado: (2022)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US
por: Lewandowska, Magdalena, et al.
Publicado: (2020)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
por: Taxonera, Carlos, et al.
Publicado: (2021)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qm94ugbqd5cim7r9cd4tgvnvmo